Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nathan Cherrington
University of Arizona, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bristol-Myers Squibb
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The Financial Entity is a publicly-traded, for-profit company engaged in the business activity of prescription pharmaceuticals and biologics. The Investigator has disclosed that he receives compensation for his consulting work for the Financial Entity. He has also disclosed that a royalty agreement is being worked out between the Financial Entity and the awardee's institution; however, the Investigator has stated that the license of IP (owned by awardee's institution) is still in negotiations and that the royalty agreement is being worked out (i.e., no royalties have been paid).
The Investigator has disclosed that the products, technologies, and activities of the entity are related to the subject of the research. The financial entity will license the technology being evaluated, studied, or utilized. The research involves intellectual property invented or developed by the Investigator. The research is designed to support new indications or applications of the intellectual property invented by the Investigator. The research results could affect the value of the Financial Entity.
Renal Disposition in NASH
PROJECT NARRATIVE Humans vary widely in their response to drugs and toxicants, which is the result of differences in the way their bodies metabolize and eliminate these compounds. Disease states that alter the ability of the kidney to eliminate these compounds could result in increased toxicity. The current application focuses on the effect of liver disease on renal secretion pathways for drug elimination and whether altered secretion makes these individuals at greater risk of toxicity.
Filed on April 08, 2019.
Tell us what you know about Nathan Cherrington's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Nathan Cherrington filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nathan Cherrington | University of Arizona | Conflict of Interest | Bristol-Myers Squibb | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.